The fungus that has long been linked to the death of the archaeologist who uncovered King Tutankhamun’s tomb may now have a role in saving lives. Researchers have utilized the toxic bacteria Aspergillus flavus—often associated with the so-called “Pharaoh’s Curse”—to develop a potent new compound capable of killing cancer cells.
A study published in Natural Chemistry Biology revealed that the fungus produced previously unknown molecules, which the research team subsequently corrected and tested against human leukemia cells.
Two compounds known as asperigycin exhibited strong anti-cancer activity. After correction, one variant, along with two FDA-approved drugs, was effective in eliminating cancer cells.
“We know that fungi have significant potential to generate bioactive molecules,” stated senior author Professor Sherry Gao in an interview with BBC Science Focus. “However, only a small fraction of these possible molecules has been discovered.”
A. flavus carries a grim legacy. Following the opening of King Tut’s tomb in the 1920s, a wave of fatalities fueled the myth of the Pharaoh’s curse. Subsequent investigations indicated that spores of A. flavus, sealed within the tomb for millennia, could have triggered deadly pulmonary infections.
A similar incident occurred in the 1970s, where 10 out of 12 scientists who entered the tomb of a Polish king died shortly after exposure to the fungus.
Now, the same lethal fungus may catalyze a medical advancement. The research team discovered that A. flavus produces a type of molecule called RIPP, short for ribosome-synthesized post-translationally modified peptides.
These molecules are known for their intricate structure and significant biological effects, yet few have been identified from fungi.
The team isolated four peptides featuring a distinctive ring-shaped structure. When tested on cancer cells, two were particularly effective against leukemia. The third, artificially modified with a fatty molecule known as a “lipid chain,” exhibited effects similar to conventional chemotherapeutics like cytarabine and donorubicin.
“After modification, the compounds were better at entering the cell,” Gao explained. “I believe that once inside, there is a mechanism to inhibit cell division.”
GAO noted that further research is essential to understand how RIPPS target cancer cells and why they are effective against leukemia but not other tested cancer types.
According to GAO, the team aims to develop a platform to identify more potentially beneficial products derived from fungi.
“Nature has gifted us this incredible pharmacy,” Gao remarked in a statement. “It is up to us to uncover that secret.”
Read more:
About our experts
Xue (Sherry) Gao serves as an Associate Professor of President Pen Compact at the University of Pennsylvania. Her laboratory is focused on developing highly specific and effective genome editing tools for diverse applications in disease treatment, diagnosis, and the exploration of new small molecule drugs.
Source: www.sciencefocus.com
